SCHEMBL25359894

SCHEMBL25359894

COC(=O)c1cccc(S(=O)(=O)Nc2nc(Cl)c(OC)c(-c3c(C)cccc3C)n2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC40A1 Q9NP59 1/20 0.47
▸ ACLY P53396 2/20 0.44
▸ TCF4 P15884 2/20 0.43
▸ CTNNB1 P35222 2/20 0.43
▸ HSPD1 P10809 1/20 0.42
▸ PTPN2 P17706 1/20 0.42
▸ PTPN1 P18031 1/20 0.42
▸ PTPN5 P54829 1/20 0.42
▸ HSPE1 P61604 1/20 0.42
▸ ALDH1A1 P00352 4/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ PLAU P00749 2/20 0.41
▸ PLAT P00750 1/20 0.41
▸ CYP2C9 P11712 2/20 0.40
▸ CA1 P00915 2/20 0.40
▸ CA2 P00918 2/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ LOX P28300 1/20 0.39
▸ CA12 O43570 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29515216 1.00 SLC40A1 (0.47) SLC40A1ACLYTCF4CTNNB1HSPD1
SCHEMBL24332218 0.92 TSHR (0.46) ACLYALDH1A1MEN1KMT2ACA1
SCHEMBL29515246 0.92 TSHR (0.46) ACLYALDH1A1MEN1KMT2ACA1
SCHEMBL29515336 0.91 SLC40A1 (0.44) SLC40A1ACLYTCF4CTNNB1HSPD1
SCHEMBL29515366 0.90 SLC40A1 (0.48) SLC40A1ACLYTCF4CTNNB1HSPD1
SCHEMBL24330996 0.90 SLC40A1 (0.48) SLC40A1ACLYTCF4CTNNB1HSPD1
SCHEMBL24331458 0.88 SLC40A1 (0.47) SLC40A1ACLYTCF4CTNNB1HSPD1
SCHEMBL24330985 0.88 SLC40A1 (0.49) SLC40A1ACLYTCF4CTNNB1HSPD1
SCHEMBL29515423 0.88 SLC40A1 (0.49) SLC40A1ACLYTCF4CTNNB1HSPD1
SCHEMBL29515546 0.88 SLC40A1 (0.47) SLC40A1ACLYTCF4CTNNB1HSPD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230365587-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS (SAN DIEGO) LLC 2023-11-16 — — US disclosed
US-20230365587-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS (SAN DIEGO) LLC 2023-11-16 — — US disclosed
EP-4225762-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR Vertex Pharmaceuticals Incorporated (US) 2023-08-16 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365587-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B SLC40A1 801/4885ACLY 1331/4885TCF4 1482/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback